Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) have been given a consensus rating of “Buy” by the twelve ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $21.71.

Several research firms have recently weighed in on CYTK. ValuEngine raised Cytokinetics, from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics, in a research report on Friday, May 19th. Zacks Investment Research lowered Cytokinetics, from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 4th. Cowen and Company reaffirmed an “outperform” rating and issued a $19.00 target price (up from $17.00) on shares of Cytokinetics, in a research report on Saturday, April 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Cytokinetics, in a research report on Tuesday, April 25th.

Shares of Cytokinetics, (NASDAQ:CYTK) traded up 1.96% during midday trading on Tuesday, hitting $13.00. The company’s stock had a trading volume of 168,977 shares. Cytokinetics, has a 1-year low of $8.51 and a 1-year high of $17.20. The company has a market cap of $586.08 million, a P/E ratio of 175.68 and a beta of 1.97. The company has a 50-day moving average price of $13.99 and a 200 day moving average price of $12.72.

WARNING: “Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of “Buy” from Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/11/cytokinetics-incorporated-nasdaqcytk-receives-consensus-recommendation-of-buy-from-analysts.html.

In other Cytokinetics, news, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $12.14, for a total transaction of $60,700.00. Following the completion of the sale, the chief executive officer now directly owns 88,385 shares of the company’s stock, valued at approximately $1,072,993.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.20% of the company’s stock.

A number of hedge funds have recently modified their holdings of CYTK. FMR LLC increased its position in shares of Cytokinetics, by 2.7% in the fourth quarter. FMR LLC now owns 5,199,414 shares of the biopharmaceutical company’s stock worth $63,173,000 after buying an additional 136,758 shares during the last quarter. A.R.T. Advisors LLC acquired a new position in shares of Cytokinetics, during the fourth quarter worth $394,000. Norges Bank acquired a new position in shares of Cytokinetics, during the fourth quarter worth $976,000. Teachers Advisors LLC increased its position in shares of Cytokinetics, by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 53,278 shares of the biopharmaceutical company’s stock worth $647,000 after buying an additional 2,025 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Cytokinetics, during the first quarter worth $4,302,000. 58.46% of the stock is owned by hedge funds and other institutional investors.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.